Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Reading its earnings reports, it’s apparent that BMY is experiencing the same problems that AMRN faced years ago. Sales of key drugs have fallen, notwithstanding multiple and extensive TV ads directed to patients and doctors. A few of those drugs will have generic competition on patent expiration in addition to negotiated price reduction in light of recent Congressional legislation. 2500 person layoffs are in the future for BMY. Debt accrued for a pair of acquisitions this year also is a problem in light of much higher interest rates in 2024, in contrast to AMRN that has no debt.
BTW, we deliberately purchased those 100 AMRN shares at $0.9638/share AH last evening. I had intended to purchase up to 900 more but a retirement party we attended lasted beyond last trade at 8 pm.
Some sad history: New Jersey Rep. Donald Payne Jr. dies from a cardiac episode related to complications from diabetes at age 65. He had been hospitalized, unconscious, since early April, per reports in N.J. newspapers.
How does fat help? Does the source of fat (e.g., nuts) make a difference?
Have you picked a date for contest 20 to start?
The total triglyceride-lowering market is ~7% of the total market that Amarin is aiming at. The remaining 93% is the CVD market for which no generic has an FDA-approved ANDA or sANDA.
Let’s continue this debate tomorrow. We don’t seem to have helped Amarin share price today. I just received a news alert about an explosion at an Iran oil refinery. That news may have a further negative effect on all sectors of the market tomorrow but for the defense industry sector.
Ask sleven or CaptBeer to find the original Complaint that Amarin filed in the Nevada court. The 6 patents will be cited there that H and DRL were accused of infringing. It’s past dinner time for me.
Question to both Stockboy and BbI: Were all claims of Amarin’s 6 patents involved in the Nevada suit limited to IPE, icosapent ethyl, as opposed to defined amounts of highly pure EPA? Thanks to both of you for your analysis. Restoration of some claims of those patents, particularly the dependent claim you focus on, could still be waved in front of H’s face to force a possible settlement. The Supreme Court’s opinion in Hazel-Atlas remains in play, IMO. DRL and TEVA should also be concerned.
So far C has been right on his calls re AAPL and NVDA: Buy at a lower price(whatever that price is), hold and do not sell(unless you bought at the all time high and need a tax loss). I will abide by that recommendation.
He stuck a Pitchfork in AMRN last year: “Too speculative, stay away, do not buy.” He may now be missing a recovery with Amarin’s Vascepa now approved and reimbursed in all Canadian provinces; approved in China, Australia and New Zealand; approved by EU(EMEA) with reimbursement in UK, SPAIN, and being negotiated in remaining countries of EU; FDA approved in U.S., with patient’s insurance permitting Amarin to maintain a 57% market share against 5-6 generics who have no sANDA approved by FDA for Vascepa treatment of the much broader CVD indication. Take a look at the posters/abstracts featuring Vascepa that were presented at ACC earlier this month.
Typo: “cerebral” should read “cerebrospinal(CBS)”.
Do the patient’s cerebral blood flow biomarkers being investigated in BRAVE also include Lp(a)?
Does anyone remember whether BRAVE clinical trial includes the observation/measurement of patient’s Lp(a) levels in the respective Vascepa treatment and placebo arms?
CaptBeer, the graph in your post is the most complete summary of Reduce-It trial results that I have seen. The authors of the large U.Cal.Irvine Lp(a) study(lead investigator Wong et al), posted by DMC8, were obviously unaware of the data presented by Bhatt et al at ACC (that was the subject of several abstracts/posters also published in JACC) when they said there is “no treatment available yet.” My wife and I are signing up for a Lp(a) test.
Shares of Amarin are currently trading at an unjustified low value. Has there been a leak of results of proxy votes submitted on April 12 due date?
I agree—icosapent ethyl is not found in fish, but was manufactured/synthesized in a laboratory by its inventors.
I have a chart showing the content of omega-3 in various fish. Chewing on salmon, smoked salmon, smoked brook trout seems to increase the benefit of Vascepa for me while tilapia flunks.
Another ambiguity: In our TD Ameritrade account remaining, the Latest Earnings Announcement is set for today, 4/15/2024, but it sets the Upcoming Earnings Announcement as 4/18/2024. I gather 4/18 is correct.
Iran’s drone attack against Israel has begun, per news alert just received.
Beamr(BMR) is one of the early partners of NVDA mentioned in your post. NVDA shareholders should investigate BMR’ s website and PRs to see the image reduction technology that BMR brings to the table to enhance the share value of NVDA. We hold 600 shares of BMR, currently quoted at $6.20/share. We also hold 755 shares of NVDA at a split-adjusted cost or basis of $4.3115/share, purchased over a decade ago. Ready for another NVDA stock split.
Looked at ALPN very early this morning but, before I was able to accumulate funds in IRA to buy, it had already advanced in share price to near acquisition value. Gave up on what looked like a good play—will look at the other one over the weekend.
Some of us will remember the essentially “free advertising” Amarin obtained when the top-line and final data results from Reduce-It clinical trial were released in 2019-2020. Long stories with video interviews of Amarin’s CEO, Dr. Bhatt and various other knowledgeable cardiologists and endocrinologists were featured in the Washington Post, New York Times, Wall Street Journal and Bloomberg(Vascepa “works”, said JT), among many others. Prospective patients and prescribing doctors read those stories.
I am confident that Amarin management and BOD, and Sarissa/Dr. Denner will find a timely way to make those publications aware of Vascepa’s new CVD risk reduction and other disease treatment data that Amarin has accumulated since, particularly the data released this past week at the ACC scientific session—why and how Vascepa “works.”
Not only “what they are generic for”, but “what they are not shown with evidence to be generic for” would be better, IMO, in light of the facts of this case. The fact that FDA has approved the generic for one indication but has not approved the generic for another, second indication should be part of permissible conduct to escape infringement.
New York Times reports a FAA whistleblower investigation re design flaws in Boeing Dreamliner.
Thanks for the link and “dialog” between you and jfmcrr. My PCP, a former NIH research physician, prescribed tadalafil for me a few years ago. Both my retina specialist and ophthalmologist were happy to see it on my med list also after my cataract removal. I have no cardiologist that I regularly see.
I’ve read a report that the plane involved was manufactured by BA in 2015, in service for 9 years. This shifts the Denver incident to LUV(Southwest) maintenance.
New investigation initiated against Boeing after engine cowling fell off 737-800, hitting wing tip, Denver incident today, per Reuters.
dewophile, I didn’t realize the above link is a duplicate of what you posted, and forgot that when I read NEJM w/o our subscription copy in front of me that I need our password to read the entire text. Our local public library does not subscribe to NEJM or Lancet, but the librarian will be happy to provide an on-line view if I pay a fee. Is Google Scholar to be included in the new subscription-based service that Google’s CEO said will soon be introduced(CNBC-TV a few days ago)?
DOI: 10.1056/NEJMoa2312323
Above is from NEJM that I have read.
I would advise TD Ameritrade to replace the quotation I see with the full quote you see from the Webpage. That would remove an ambiguity that is adversely affecting CDMO share price, IMO. Have you contacted CDMO CEO and BOD regarding this ambiguity? I am an old shareholder that perhaps should have immediately known that “Which We All Knew.” I didn’t. Would new shareholders know? Would market makers and short sellers take advantage of the ambiguity to keep CDMO share price low?
At the very top of a TD Ameritrade CDMO stock quote, I get a notice that reads:
“Common Stock Status Alert: Delinquent”
I have a question; the answer could affect everyone here. If CDMO has paid the delinquency debt due, why am I getting a delinquency alert from TD Ameritrade today? Is TDA delivering false information that is affecting CDMO share value?
biopa, for some reason(relating to a “hidden identity”) I can’t respond directly to your most recent message. Suffice to say, I think if you trace my name and posts on the Amarin message board you will have my current assessment of where we shareholders and Amarin now stand. In short, I am more optimistic. I will have a better assessment after 1) the decision and opinion of the CAFC is released, and 2) Amarin’s posters and abstracts are presented this weekend, particularly Sunday’s poster that ACC says I need a meeting key to open and read. Maybe kiwi or exwannabe have a key and can open it to post the text. 3) I have not read the text and claims of the new patent to be granted by EU authorities either.
Meantime I suggest you read the article appearing at elaine.chen@statnews.com. Dew Diligence provides a link at post # 251995 on the Biotech Value board. Ask yourself: Does this article relate in any way to the Phase 3 BRAVE clinical trial that is examining the effect of Vascepa as a biomarkers diagnostic of dementia and AD?
Amarin needs to increase the number of patients in the U.S. and the rest of world who are prescribed Vascepa to reduce risks from CVDs.
This week PLTR/ORCL and CDIO/Navierre have established a pair of separate collaborations that are designed to make AI-driven diagnostic algorithms for detecting patient risks of CVDs available to those patients who live in less-populated rural areas. Potential patients( e.g., those in wheelchairs that may have such risks) simply have not been driven/travelled to urban areas of USA to obtain the use of trained cardiology clinicians and complex/expensive imaging devices. We have seen here that trained cardiologists do/will prescribe Vascepa by email to pharmacies in urban areas for patients or caregivers to pickup.
I do. 1). I have not seen the text of AMRN’s answer/reply to DRL’s motion that the magistrate judge in Trenton ordered be filed by AMRN on March 28. Does anyone have the text of what Amarin said?
2). A brief summary: IMO, AMRN has the potential option of filing a new complaint in Nevada or Trenton(or an amended complaint) asking for relief in the form of restoration of the patents held invalid in Nevada to a state of validity. AMRN would rely on the gist of the “fraud on the court” arguments that we shareholders presented to both the CAFC and S.Ct. IMO, the quoted inequitable conduct/ethics Hikma/DRL used to invalidate the patents would wipe out any question/issue of res judicata or collateral estoppel raised by DRL or HIKMA . The 1940s S.Ct. Hazel-Atlas decision/opinion by Justice Black is controlling authority.
3). All judges today, IMO, appear to have remarked that Hikma’s product label, coupled with a website and/or a PR, actually presented a case/issue of whether Hikma had directly infringed the AMRN patents under 35 U.S.C. 271(a). We need a follow-up, like court-ordered discovery, on that point.
At this point, it would be helpful to know if the antitrust case in N.J. has been, or will be, consolidated with the patent infringement case against Hikma in Delaware. Where will it be consolidated? A 3 judge panel of Circuit Judges normally decides such matters.
Spouse and I were going to watch/hear in person. One of us mixed up the date, and she scheduled April 5. We are talking about rescheduling now. We’ll see how that turns out.
You have a correct viewpoint, CaptB. Appearance of PTO examiners in federal courts has declined to near nil since the Tetracycline days many decades ago.
We have seen TEVA importing IPE to those Florida and New Jersey locations as well as Vancouver and Seattle locations. You earlier told me that you were unable to trace where those East Coast shipments went after landing in port. Were those shipments sent by truck to AMRN’s capsule processing/finishing supplier in S. Carolina or stored for use in any TEVA processing facility in Fla. or N.J.? We have seen, I think, TEVA settle its Marine ANDA litigation early to obtain a more favorable time of entry into the market from AMRN versus other generics that did not settle.
I suggest some possibilities: 1) TEVA merges with AMRN, and uses AMRN’s patented finish process to ultimately send finished dosage forms(including those of Mochida?) to Asia. 2). TEVA knows of PFE sales of Vascepa in all of Canada. PFE merges with AMRN. TEVA sells and airships its imported IPE to PFE in San Diego for use in its bioreactor plants there or to other independent plants along the West Coast. Same result for PFE as related in 1) above.
CDMO’s CEOs over the years, even recently, have distinguished between early and late stage customers in earnings conference calls. Pre-clinical or Phase 1-2a clinical trial customers were referred to as early stage that require less quantity of material for testing for results. Smaller size bioreactors would be used to produce that material. Conversely, late stage customers— those whose meds are in Phase 2b or Phase 3 clinical trials—often/always need material/med quantities that are sufficient for commercial sale once FDA approves an NDA. Larger bioreactors would produce that med.
A few press releases about identity of early or late stage customers would help, I think
Does anyone have any comments on the abstracts and theater presentations posted by triple? Or is too early w/o full text?